The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation, while its consumer healthcare business, Haleon ... elements of the ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts ... pure-play since the spin-off of Haleon in July – also raised its ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019.